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Abstract
Reducing the risk of dementia can halt the worldwide increase of affected people. The
multifactorial and heterogeneous nature of late-onset dementia, includingAlzheimer’s
disease (AD), indicates a potential impact ofmultidomain lifestyle interventions on risk
reduction. The positive results of the landmark multidomain Finnish Geriatric Inter-
vention Study to Prevent Cognitive Impairment and Disability (FINGER) support such
anapproach. TheWorld-WideFINGERS (WW-FINGERS), launched in2017and includ-
ing over 25 countries, is the first global network of multidomain lifestyle interven-
tion trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt,
test, and optimize the FINGER model to reduce risk across the spectrum of cognitive
decline—from at-risk asymptomatic states to early symptomatic stages—in different
geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and
adapt multidomain interventions across various countries and settings, to facilitate
data sharing and analysis across studies, and to promote international joint initiatives
to identify globally implementable and effective preventive strategies.
KEYWORDS
Alzheimer’s disease, cognitive impairment, dementia, lifestyle, multidomain intervention, preven-
tion, randomized controlled trial,World-Wide FINGERS
1 INTRODUCTION
Worldwide, nearly 50 million people are living with dementia.
Alzheimer’s Disease International (ADI) predicts this number will
reach nearly 82 million in 2030 and over 152 million in 20501 unless
interventions are identified and implemented to prevent or delay
onset, slow progression, or stop Alzheimer’s disease (AD) and other
disorders that cause dementia. Indeed, delaying the onset of AD by
only a few years could substantially reduce its prevalence and related
human and economic burdens.2
Several studies published in recent years suggest a decline in the
age-adjusted incidence of dementia, with stable or reduced preva-
lence, in Western countries including the United States,3,4 Sweden,5,6
the United Kingdom,7 and The Netherlands.8 Other studies, however,
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indicate an increased incidence in some Asian countries, such as
China and Japan.9-12 Factors that may have contributed to a lower
occurrence of dementia in some countries relate to changes in risk fac-
tor profiles, including improved treatment for hypertension, diabetes,
and other vascular risk factors,13 as well as increased educational
opportunities.3 A meta-analysis of population-based observational
studies from the United States and Europe concluded that about 30%
of AD cases may be attributable to seven potentially modifiable risk
factors for AD—diabetes, midlife hypertension, midlife obesity, physi-
cal inactivity, depression, smoking, and low educational attainment.14
This study and others have concluded that targeting these risk factors
may represent a powerful strategy for risk reduction of AD. Given the
complex, multifactorial, and heterogeneous nature of late-onset AD
and dementia, interventions targeting several risk factors and mech-
anisms simultaneously may be required to achieve optimal preventive
effects.15
The Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment andDisability (FINGER, ClinicalTrials.gov:NCT01041989)
represents the first large, long-term randomized controlled trial (RCT)
demonstrating that a multidomain lifestyle intervention can improve
cognitive function in older adults from the general population who are
at elevated risk of developing dementia.16 Participants in the trial were
randomized to either a group that received general health advice or a
group to be enrolled in a 2-yearmultidomain intervention that incorpo-
rated dietary counseling, physical exercise, cognitive training, and vas-
cular andmetabolic riskmonitoring.17 Improvement in global cognition
after 24 months, assessed using the comprehensive Neuropsycholog-
ical Test Battery (NTB total score), was 25% higher in the multidomain
intervention group than in the general health advice group (P = .03).
Performance was improved in all cognitive sub-domains including
executive function, processing speed, and complex memory tasks.16
Further analyses showed that the FINGER multidomain intervention
benefited cognition regardless of sociodemographic and socioe-
conomic factors or other baseline characteristics, supporting the
potential benefits of the FINGERmodel for large at-risk populations.18
Individuals with genetic susceptibility (apolipoprotein E gene (APOE)
ε4 carriers) showed cognitive benefits from the intervention.19 The
FINGER intervention also reduced the risk of developing new chronic
diseases.20 Extended 5- and 7-year follow-up assessments have been
completed recently and data analysis is ongoing to measure the long-
term effects of the intervention. Although the FINGER trial results
were encouraging, two other large multidomain RCTs—the French
Multidomain Alzheimer Preventive Trial (MAPT) and the Dutch Pre-
vention of Dementia by Intensive Vascular Care (PreDIVA)—reported
lack of effect on the primary outcomes.21,22 Remarkably, exploratory
subgroup analyses in both studies provided evidence that interven-
tions yielded cognitive benefits in subpopulations of participants
with increased risk of dementia,21-23 highlighting the importance of
methodological issues such as selection of at-risk individuals, adequate
timing and intensity of the interventions, and selection of appropriate
sensitive tools to detect changes in cognition. Overall, the potential
of multidomain interventions for dementia risk reduction and preven-
tion needs further validation, and there is a need to test and adapt
RESEARCH INCONTEXT
1. Systematic review: The Authors met in 2 occasions (plus
additional teleconferences and smaller working-groups
meetings) to discuss adaptation and testing of the FIN-
GER multidomain prevention model in different settings
and populations. The development of a scientific method-
ology was supported also by search (PubMed, Authors’
own reference catalogues) for RCTs to prevent cognitive
impairment or dementia, which target multiple lifestyle
factors simultaneously. Ongoing and completed trials
were identified and discussed. These studies are appro-
priately cited.
2. Interpretation: The FINGER model has shown beneficial
effects on cognition in at-risk seniors. Themodel needs to
be further tested, adapted and optimized in diverse geo-
graphical and cultural settings. Within the World-Wide
FINGERS Network, a scientific methodology has been
outlined towards this goal.
3. Future directions: Ongoing and planned trials within the
World-Wide FINGERS Network will investigate feasibil-
ity and efficacy of the FINGER intervention in differ-
ent populations, and generate data for evidence-based
knowledge for globally implementable and effective pre-
ventive strategies for cognitive impairment, dementia
and AD.
HIGHLIGHTS
∙ Prevention is pivotal to reduce theoccurrenceofdementia
worldwide
∙ The Finnish Geriatric Intervention Study to Prevent Cog-
nitive Impairment andDisability (FINGER) trialmodel sup-
ports the benefits of multidomain lifestyle interventions
∙ The World-Wide FINGERS (WW-FINGERS) network is
testing and adapting the FINGERmodel globally
∙ WW-FINGERS is a unique network supporting data har-
monization and sharing
∙ WW-FINGERS can lead to effective and feasible dementia
preventive strategies
these approaches in diverse geographical, economic, and cultural
settings.
The Lancet Commission on Dementia Prevention, Intervention, and
Care proposed a life-course model of dementia risk that reflects how
lifestyle factors across the lifespan contribute to dementia risk. They
estimated that interventions across the lifespan could theoretically
prevent more than a third of dementia cases. These interventions
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include increasing access to and quality of education in early life; treat-
ing or reducing hypertension and obesity inmidlife; addressing hearing
loss; and reducing smoking, depression, physical inactivity, social isola-
tion, and diabetes in late life.24
In 2017, the National Institute on Aging (NIA) asked the National
Academies of Science, Engineering, and Medicine to convene a com-
mittee to explore evidence regarding interventions with the poten-
tial to prevent or slow cognitive decline and dementia. Although it
found insufficient high-strength evidence to justify a public health cam-
paign to encourage people to adopt lifestyle interventions to prevent
dementia, the committee acknowledged that this may reflect method-
ologic inconsistencies across clinical studies. They also cited results
from the FINGER trial as providing promising data from a large and
long-duration trial of a multidomain intervention, and they suggested
replication of FINGER through multiple independent studies testing
the same components.25 In addition, dementia risk reduction is one
of the strategic action areas of World Health Organization’s (WHO’s)
Global action plan on the public health response to dementia 2017-
2025. The recently published WHO Guidelines for risk reduction of
cognitive decline and dementia provide evidence-based recommenda-
tions to support countries as they develop approaches to delay or pre-
vent the onset of dementia. The guidelines highlight the importance of
further research on the efficacy of multidomain interventions that are
adjusted to specific geographical and cultural contexts.26
In line with these indications, the launch of the World-Wide
FINGERS (WW-FINGERS) Network was announced at the 2017
Alzheimer’s Association International Conference (AAIC) in London.27
The Network aims to test the FINGER multidomain lifestyle model
in various populations and settings. Harmonization across trials is
paramount, yet adaptations will be needed to ensure acceptance
of and adherence to interventions, as well as assessments among
populations that are appropriate in terms of language, ethnicity,
culture, environment, and risk of AD and dementia. TheWW-FINGERS
Network held two face-to-face meetings in connection with AAIC: the
first on July 20, 2018, in Chicago, and the second on July 12, 2019,
in Los Angeles. Periodic teleconferences and ancillary meetings have
been also held regularly to move forward with the Network activities.
This report summarizes the proceedings of the first two face-to-
face meetings, which are now repeated yearly in connection with
AAIC.
2 WW-FINGERS NETWORK STUDIES
WW-FINGERSwas established to support and convene globalmultido-
main dementia prevention trials, share experiences and data, as well
as harmonize methods. The aim is not to replicate the original FIN-
GER intervention, but rather to adapt and optimize it to various set-
tings, to test whether FINGER-based protocols are feasible and effec-
tive in various populations. Methodological pillars of WW-FINGERS
trials include: assessmentof amultidomain intervention aiming to ame-
liorate vascular, metabolic, and lifestyle-related factors; delivery of the
intervention through individual and group sessions to optimize the
intervention at an individual level but also stimulate social interaction
andpeer support; prospectiveharmonizationof cognitiveoutcomes (ie,
assessment of cognitive changes) as well as other outcomes; and use
of randomization to support balanced comparisons among interven-
tion conditions. The network includes investigator teams from around
the world, with the aim of building on “lessons learned” from previous
studies and expand the knowledge on feasibility and efficacy of mul-
tidomain interventions for risk reduction and prevention of dementia
in diverse populations.27 At the time of the WW-FINGERS Network
meeting in 2019, over 25 countries had joined, andWW-FINGERS tri-
als had been planned in several European countries, USA, China, Sin-
gapore, South Korea, Japan, and Australia. Currently, similar efforts
are ongoing in Central and South America, Canada, India, andMalaysia
(Table 1 and Figure 1).
WW-FINGERS comprises studies at different stages of implemen-
tation and with varying gradations of alignment to the FINGER trial
(Table 1). For instance, in theU.S. study toProtect BrainHealth through
a Lifestyle Intervention to Reduce Risk (U.S. POINTER), the interven-
tions and outcomes are harmonizedwith FINGER. This consistencywill
allow for numerous cross-study comparisons as data become available
in U.S. POINTER. A number of feasibility studies are evaluating the
ability to conduct such a trial in a particular country and/or popula-
tion, whereas other studies are in the initial stages of discussion and/or
implementation (Table 1 and Figure 1). To help classify and understand
the status of the WW-FINGERS trials, the network has agreed on the
definition of four main levels, which reflect the trials’ key features,
including current status (eg, from RCTs still in the planning stage to
those in which follow-up of participants is available); funding availabil-
ity; and degree of alignment with the FINGER RCT, in terms of design,
intervention being tested, and assessment of cognitive outcomes (Fig-
ure 2). Each study in the WW-FINGERS Network can be assigned to a
level, andmovement among levels is expected.
The next sections summarize the WW-FINGERS Network studies
(see also Table 1), followed by a section discussing the key issue of data
sharing and harmonization, and a final section on future steps needed
to advance the Network activity.
2.1 U.S. POINTER
In the United States, the U.S. POINTER study (ClinicalTrials.gov:
NCT03688126) will enroll approximately 2000 cognitively normal
adults who are at an increased risk for cognitive decline and demen-
tia in later life. Increased risk is defined by sedentary lifestyle, poor
diet, and other factors such as suboptimal cardiovascular health sta-
tus and first-degree family history of significant memory impairment.
At five sites across the country, participants will be randomly assigned
to a self-guided or structured lifestyle intervention program focused
on increasing physical exercise, consuming a healthy diet, intellectual
stimulation and social engagement, and health monitoring to man-
age cardiovascular risk factors. The primary outcome is change in
global cognition, assessed by a composite score that is harmonized
with the primary outcome in FINGER. Other measures will include
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1086 KIVIPELTO ET AL.
F IGURE 1 Worldmapwith countries that are involved in theWorld-Wide FINGERSNetwork. Dark blue indicates involvement in ongoing
World-Wide FINGERS studies. Studies are currently planned in countries markedwith light blue
F IGURE 2 Levels defined for the trials participating in theWorld-Wide FINGERSNetwork
separate composite measures of episodic memory, executive func-
tion, and processing speed; self-reported changes in mood, sleep, and
lifestyle practices; walking speed; and cardiometabolic health metrics.
Intervention effects will be examined by subgroups based on APOE ε4
genotype and baseline cognitive performance. Blood samples are col-
lected and stored for future investigations of potential mechanisms
underlying intervention effects. Sub-studies will be conducted to col-
lect magnetic resonance imaging (MRI) and amyloid and tau positron
emission tomography (PET); objective measures of sleep quality; and
microbiome data. U.S. POINTER initiated recruitment in January 2019
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for the vanguard site in North Carolina. The other four sites include
Northern California, Chicago (IL), Houston (TX), and Rhode Island. The
Alzheimer’s Association funds the study and collaborates with the U.S.
POINTER Coordinating Center at Wake Forest School of Medicine
(Winston-Salem, NC, USA) to assist in leading the study.
2.2 MIND-CHINA
The randomized controlled Multimodal INtervention to delay Demen-
tia and disability in rural China (MIND-CHINA, Chinese Clinical Trial
Registry: ChiCTR1800017758) study targets residents from 52 vil-
lages in rural areas of Western Shandong Province (Yanlou Town of
Yanggu county). In March-October 2018, baseline assessments and
screenings for participants were completed, during which over 5700
subjects who were 60 years of age or older were examined. Starting
from March 2019, non-demented and non-disabled residents aged 60
to 79 are being enrolled into the MIND-CHINA Study and randomly
divided by village (a method known as cluster randomization) into
one of three groups: a group that will receive regular health care
services provided by government; a vascular intervention group that
will receive intensive medical treatment to improve the control of
three major vascular risk factors (high blood pressure, high blood
glucose, and dyslipidemia); or a multidomain intervention group that
will receive guidelines of healthy lifestyle and diet, physical exercise,
promotion of personalized leisure activities, as well as cognitive train-
ing, in addition to intensivemanagement of major vascular risk factors.
MIND-CHINA aims to recruit 3000 participants. A cognitive compos-
ite measure that involves memory, language, information processing
speed, and executive function similar to FINGER’s NTB will be used
as the primary outcome. Secondary outcomes will include physical
function, incidentmild cognitive impairment (MCI) and dementia (after
5 years of follow-up), and occurrence of cardiovascular events. In addi-
tion, a brain MRI sub-study is planned within MIND-CHINA, with core
MRI sequences including magnetic resonance angiography, structural
MRI measures, and resting-state functional MRI. MIND-CHINA is
supported by the grant from the National Key R&D Program of China
and the Sino-Sweden joint research project grants from the National
Natural Science Foundation of China and the Swedish Research
Council.
2.3 Australia—AU-ARROW and Maintain Your
Brain
Australia includes two lifestyle intervention studies that comprise dif-
ferent interventions andoutcomes.One is theAUstralian-Multidomain
Approach to Reduce Dementia Risk by PrOtecting Brain Health with
Lifestyle intervention (AU-ARROW), which will randomize 900 par-
ticipants ages 55 to 75 into one of three groups: a usual care
group; a group that will receive health education and support; and
a multidomain intervention group. The trial will run for 2 years,
with an additional 6-month follow-up. As with other FINGER stud-
ies, change in cognition is the primary outcome. Secondary out-
comes will include blood and cerebrospinal fluid (CSF) biomarkers and
brain imaging—amyloid and fluorodeoxyglucose PET, MRI, and retinal
imaging.
A second Australian study, called Maintain Your Brain
(MYB, Australian New Zealand Clinical Trials Registry:
ACTRN12618000851268) is ongoing and tests an internet-based
multidomain intervention, which if successful could provide a rela-
tively low-cost strategy to deliver potentially preventive interventions
at a population level and in particular to geographically isolated people.
To qualify for the study, individuals were 55- to 77-years-old and had
two or more lifestyle-related risk factors for dementia, including
physical inactivity, cognitive inactivity, depression/anxiety, overweight
or obesity, and poor dietary habits.28 Participants (n = 6236) were
randomized to receive a personalized multidomain intervention or
non-interactive web-based health advice and information. A unique
feature of theMYB trial is that the intervention is targeted to improve
participant-specific risk factors. The interventions are delivered in the
form of coaching modules across four thematic areas: physical activity,
diet and nutrition, cognitive training, and mood, and participants do
not need to receive the intervention in all four areas. Modules are
delivered quarterly in Year 1 followed by monthly boosters until end
of Year 3. Primary outcomes include a cognitive composite measure, in
synergy with FINGER and U.S. POINTER.
2.4 Europe—MIND-AD
The FINGER protocol is also tested in Europe (Sweden, Finland, Ger-
many, France) in the Multimodal Prevention Trial for Alzheimer’s
Disease (MIND-ADmini, ClinicalTrials.gov: NCT03249688). MIND-
ADmini is an ongoing pilot trial evaluating the feasibility of the FINGER
multidomain lifestyle intervention in prodromal AD defined according
to the International Working Group (IWG)-1 criteria.29 Participants
also havemodifiable vascular or lifestyle-related risk factors.
Conducting a feasibility trial in people who are already in the early
stages ofADandhave some cognitive impairment is important because
of the potential need for additional supportwith healthy lifestylemain-
tenance. The duration of the trial is 6months,with an optional 6-month
extension. Participants are randomized into three groups: multido-
main lifestyle intervention based on the FINGER model; multidomain
lifestyle intervention plus the medical food Fortasyn Connect; or
standard care. The rationale for combining amultidomain intervention
with medical food is suggested by studies that evaluate the synergistic
effects between different intervention components (eg, omega-3
fatty acids and physical activity). Fortasyn Connect is a multinutrient
including omega-3 fatty acids, phospholipids, choline, vitamins, and
minerals. It has been selected forMIND-AD because prior results from
another phase-2 RCT in prodromal AD suggest that a combination of
interventions should be evaluated.30
Themain aimsofMIND-ADmini are to evaluate the feasibility of and
adherence to the multidomain intervention. Exploratory aims include
intervention effects on changes in vascular and metabolic risk factors;
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depressive, anxiety, and stress symptoms; cognition; health-related
quality of life; and physical performance. Blood samples are collected
for exploring potential mechanisms and mediating pathways of the
multidomain intervention. There is also a qualitative interview study
focusing specifically on theexperiencesof the trial participants. Results
will be used in the planning of future larger trials and will serve as a
model for combining non-pharmacological and pharmacological inter-
ventions.
2.5 Singapore—SINGER
The SINGapore GERiatric intervention study to reduce physical frailty
and cognitive decline (SINGER) is a pilot study aiming to evaluate cul-
turally appropriate adaptations of the FINGER interventions, and the
feasibility of implementing this protocol in 70 seniors, aged>65 years,
with mild-to-moderate frailty and/or cognitive impairment over a 6-
month period (Table 1). Themain outcome of this pilot study is the fea-
sibility of and adherence to the multidomain intervention, as concerns
have been raised particularly about the dietary and cognitive interven-
tions,which could require novel and culturally appropriate approaches.
The aim is to develop scalable digital platforms and build partner-
ships in order to conduct a larger confirmatory RCT in 1200 elderly
community-dwelling Singaporeans who are at risk of cognitive impair-
ment and dementia. This larger study, comparing self-guided lifestyle
management versus a structured multidomain lifestyle intervention,
will also incorporateneuroimaging andbloodbiomarkers to investigate
mechanisms of action.
2.6 South Korea—SUPERBRAIN
The SoUth Korean study to PrEvent cognitive impaiRment and pro-
tect BRAIN health through lifestyle intervention in at-risk elderly
people (SUPERBRAIN, ClinicalTrials.gov: NCT03980392) is a mul-
ticenter feasibility study enrolling seniors (60 to 79 years) with at
least one modifiable risk factor for dementia. The study includes
two intervention arms—facility-based intervention and home-based
intervention—as well as a group receiving regular health advice. The
24-weekmultidomain intervention has been derived by the FINGER
model and includes five components: monitoring and management
of metabolic and vascular risk factors; cognitive training and social
activity; physical exercise; nutritional guidance; and motivational
enhancement. The trial aims to assess the feasibility of the multido-
main intervention, and includes as secondary outcomes disability,
depressive symptoms, quality of life, vascular risk factors, physical
performance, nutritional assessment, and a motivation questionnaire.
To investigate mechanisms underlying the intervention, neurotrophic,
neurodegeneration, and neuroinflammation factors, gut microbiome,
telomere length, electroencephalography, and neuroimagingmeasures
will be evaluated. Based on the study results, a large-scale RCT will
be launched to assess the effects of the multidomain intervention on
cognition.
2.7 Japan—J-MINT
The Japan-multimodal intervention Trial for prevention of dementia
(J-MINT, UMIN Clinical Trials Registry: UMIN000038671) is an RCT
that tests the effect of a multidomain intervention in subjects with
some degree of cognitive impairment (Table 1). The study will recruit
440 older people (65- to 85-years-old) with a high risk of dementia,
defined as decreased cognitive performance in at least one of the four
cognitive functional domains of memory, attention, executive function,
and processing speed. Subjects will be randomized to either a group
that receives usual care or a group that participates in an 18-month
multidomain intervention, consistingof exercise, nutritional counseling
(visits and telephone follow-ups by health consultants with expertise
in nutrition), and cognitive training using the “Brain HQ” program. In
the exercise program, the intervention group participates in activities
described as “cognicise,” from the combination of thewords “cognition”
and “exercise”—a program developed at the National Center for Geri-
atrics andGerontology, NCGG in Japan, which combines physical exer-
cise and cognitive tasks. In addition, diabetes, hypertension, and dys-
lipidemia are treated in accordance with the Japanese guidelines for
older patients.
The primary outcome of J-MINT is cognition, whereas the sec-
ondary outcomes include functional status, blood-based biomarkers
reflecting amyloid beta (Aβ) accumulation in the brain, omics analysis,
and neuroimaging (MRI). Evidence from this research is expected to
informa large-scale, national implementation ofmultidomain interven-
tion programs for older people at high risk of dementia.
2.8 Spain—GOIZ-ZAINDU and PENSA
GOIZ-ZAINDU (Basque words for “caring early”) is an ongoing pilot
RCT that tests the feasibility of the FINGER multidomain intervention
model in the Basque population in Spain. Participants, age 60+ years,
have been recruitedwithin theGOIZ-Alzheimer cognitive decline early
detection program, using inclusion criteria similar to those used in the
FINGER RCT: increased risk of dementia, based on a CAIDE (Cardio-
vascular Risk Factors, Aging, and Incidence of Dementia) Dementia
Risk score of six points or higher,31 and lower-than-expected cogni-
tive performance in at least one of three brief cognitive screening tests
(AD8 questionnaire, Fototest, memory alteration test).32-34 Since the
RCT started in June 2018, over 250 participants have been screened,
and 125 fulfilled the inclusion criteria. Stratification by cognitive sta-
tus (MCI and normal cognition) and age (75 or older) has been per-
formed before randomization to a multidomain intervention or to a
group receiving standard health advice. The multidomain intervention
lasts 1 year and includes nutritional counseling, physical activity, cog-
nitive training, and monitoring of vascular risk factors. The study will
be completed by June 2020, and the outcomes include adherence to
the intervention, change in the CAIDE risk score, and global cognition,
measured with the NTB. Results from this pilot study will pave the
way to larger efficacy trials in the Basque country to provide knowl-
edge for public health strategies on healthy-active aging and dementia
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prevention. TheGOIZ-ZAINDUproject is performedand fundedby the
CITA-Alzheimer Foundation in collaboration with the Municipality of
Beasain andOsakidetza (the public Basque Health System).
Another study in Spain, the “Prevention of cognitive decline
after a multimodal intervention combined with epigallocatechin gal-
late in APOE4 carriers with subjective cognitive decline” (PENSA
study: in Catalan PENSA means “think about”; ClinicalTrials.gov:
NCT03978052) is an ongoing project in Barcelona, performed in
collaboration with the Hospital del Mar Medical Research Institute
(IMIM) and the BarcelonaBeta Brain Research Center (BBRC). PENSA
will randomize 200 individuals meeting criteria of subjective cogni-
tive decline (SCD), fulfilling four SCD plus features, including sub-
jects older than 60 years and APOE4 carriers. The project combines a
multidomain lifestyle intervention including diet, physical activity, and
cognitive stimulation and training and the administration as dietary
supplement of the flavanol from green tea, epigallocatechin gallate
(EGCG, 5 to 6 mg/kg up to 532 mg/day). The intervention will last
12 months. Participants will be randomized into one of four study
arms (Table 1), and the primary outcome is global cognition mea-
sured with the ADCS Preclinical Alzheimer Cognitive Composite-Plus-
exe. Secondary andexploratoryoutcomes includeneuroimaging (struc-
tural and functional MRI); microbiota; neuroinflammation biomarkers;
metabolomics; blood, brain-derived exosomes, and CSF neuropatho-
logical biomarkers; physical activity, dietary assessments, cognitive
training performance, andquality-of-life records. Theproject is primar-
ily funded by theAlzheimer’s Association, with additional support from
the Spanish Ministry of Science, Innovation and Universities (Instituto
Carlos III).
2.9 CANADA—CAN-Thumbs-UP
In Canada, the Canadian Therapeutics Platform Trial for Multido-
main Interventions to Prevent Dementia (CAN-Thumbs-Up) is in
development and will include the recruitment of a platform trial-
ready cohort of participants identified as being at increased risk
of dementia. This cohort will initially participate in an online Brain
Health Support Program (BHSP) for up to 1 year, aimed at improv-
ing dementia literacy, self-efficacy, and engagement. It will include
remote assessments during the BHSP that will enable evaluation
of compliance, and changes in lifestyle through this educational
intervention. The platform trial-ready cohort data will support the
modeling of clinical and biomarker trajectories of the high-risk par-
ticipants, who initially will either be cognitively normal or have MCI.
These data will inform development of the master trial protocol
as well as permitting identification and tailoring of interventions
to high risk study groups. The open platform trial will particularly
focus on testing multidomain interventions, including treatments of
lifestyle, pharmaceuticals, and other types of combination treatments
in periods of up to 3 years. The primary outcome for the platform
trial is expected to be a global cognitive composite, with a range of
secondary and exploratorymeasures including blood-based and digital
biomarkers.
2.10 South and Central America—LatAm FINGER
LatAm-FINGERS is a LatinAmerican initiative gathering 14 countries—
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Domini-
can Republic, Ecuador, Mexico, Paraguay, Peru, Puerto Rico, and
Uruguay—and is open to incorporating other regional initiatives. The
consortium is developing a multidomain RCT that will enroll 1400
individuals (100 from each country) aged 60 to 77 years, who are
at a high risk of cognitive deterioration due to sedentary lifestyle
and to suboptimal metabolic-cardiovascular profile. Subjects will
be randomized to either a Systematic Lifestyle Intervention (SLI)
or a Flexible Lifestyle intervention (FLI). The SLI group will receive
dietary counseling, physical exercise, cognitive training, and control
of cardiovascular risk factors. The FLI group will receive regular
health advice. Outcomes will be measured every 6 months and will
include clinical and neuropsychological assessment harmonized with
the original FINGER and with the U.S. POINTER. The protocol also
includes collection of blood samples and MRI data for the creation
of a biobank for future research. The LatAm FINGERS has two main
objectives: first, to evaluate the feasibility of the FINGERmultidomain
lifestyle intervention in the Latin American context; second, to eval-
uate the efficacy of the SLI, primarily on a global cognition composite
score as well as on specific cognitive domains: episodic memory,
executive function, and processing speed. Analyses of the intervention
effects will consider the participants’ baseline cognition and APOE
genotyping status. LatAm-FINGERS will allow to share, compare, and
harmonize data across the participating centers, thus consolidating
methods throughout Latin America for future collaborative research in
dementia.
2.11 India FINGER
Two longitudinal cohort studies of aging—one in an urban population
and one in a rural population—are being carried out in India. In urban
Bangalore, adults 45 years or older are enrolled in a study funded by
the Tata Trusts, while in the rural Kolar district, adults 45 years or older
are enrolled in the Srinivaspura Aging, Neuro Senescence and COGni-
tion (SANSCOG) study. Similar assessments are used in both studies,
including a cognitive battery comparable to that used in FINGER and
adapted for culture and education across India, brainMRI and PET, bio-
chemical tests with a focus on micronutrient deficiency and vascular
risk factors, carotid Doppler ultrasonography, complete genetics, and
activity monitoring with wearables. The contrasts observed between
the urban and rural populations will help inform a future FINGER-
type intervention study. Thesepopulationsdiffer acrossmanydomains,
including education, language, socialization, prevalence of cardiovas-
cular risk factors, and nutritional deficiencies. For example, rural resi-
dents may be reluctant to accept dietary modification and structured
exercise programs, but there may be more acceptance of yoga as a
physical activity. Thus, a 6-month pilot study in 100 participants will
investigate whether the practice of yoga affects cognitive and imag-
ing end points. These observational studies are paramount so that
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population level data can be collected before moving into an interven-
tion phase.
2.12 Other WW-FINGERS studies
In Europe, a joint EURO-FINGERS protocol is currently being devel-
oped to aid various European countries (eg, The Netherlands, Spain,
the UK, Italy, Sweden) in establishing FINGER-like studies. Some of
the new trial design elements that may be tested include, for example,
utilizing e-health and mobile-health (m-health) tools and tailoring the
interventions to take into account specific risk profiles and combining
a multidomain lifestyle-based intervention with pharmacological
interventions. Encouraging results, in terms of acceptability and effi-
cacy of e-health interventions for dementia risk reduction, have been
recently reported in the European Healthy Aging Through Internet
Counselling in the Elderly (HATICE, ISRCTN48151589). In this 18
month multinational RCT, a coach-supported internet-based multido-
main intervention for self-management of vascular and metabolic
risk factors was tested in 2724 seniors, and the intervention was
associated with amodest improvement of the risk profile.35,36
Still in Europe, Germany is assessing key issues related to the
implementation of the FINGER model, in a pragmatic 2-year trial
(AgeWell.de, German Clinical Trials Register DRKS00013555)
enrolling 1152 at-risk seniors through general practitioners.37 In addi-
tion, Malaysia is starting the Multidomain Intervention for Reversal of
Cognitive Frailty (AGELESS) study.
3 HARMONIZATION OF TRIALS, DATA
SHARING, AND ALIGNMENT
WW-FINGERS promotes the prospective harmonization of methods
and outcomes across studies and responsible sharing of data. This will
enable joint analyses and comparisons across studies andwill generate
robust evidence to inform dementia prevention strategies. The power
of WW-FINGERS can only be realized through data sharing. In the
AD field, open and responsible data sharing has fueled tremendous
progress in the Alzheimer’s Disease Neuroimaging Initiative (ADNI),
as well as in four prevention studies that came together under the
umbrella of theCollaboration forAlzheimer’s Prevention (CAP).38 Rec-
ommendations to promote responsible data sharingwere also adopted
by a European task force through a consensus-building process.39
A vision for data sharing in WW-FINGERS has been adapted from
the Institute of Medicine (IOM) report on sharing clinical trial data.40
These principles include (1) establishing a culture of sharingwith incen-
tives for sharing data; (2) building a global platform for sharing data;
(3) establishing best practices for data sharing; (4) providing adequate
financial support for the sharing of data and allocating the costs among
all stakeholders; and (5)minimizing the risks and reducingdisincentives
for data sharing.
Integrating data from different RCTs and cohort studies into a
shared database requires that data are harmonized using existing and
accepted data standards, templates, and common data elements. Com-
mon data elements enable linkage of data across multiple studies,
increase the consistency and quality of data, facilitate comparisons,
drive efficiencies, and promote interoperability. InWW-FINGERS, har-
monization will also be promoted in study design, enrollment criteria,
selection of interventions and outcomes, and monitoring of interven-
tion adherence.Members of theWW-FINGERSNetwork recognize the
need to establish rigorous standards and harmonize these elements
before the studies begin data collection. Prospective harmonization of
theWW-FINGERS trials is being detailed in theWW-FINGERSHarmo-
nization Protocol, which is currently under development. Among the
key points, the Protocol specifies that in all trials the main principles of
the intervention are based on the experiences from the FINGER study.
It is recommended that all the basic components of the multidomain
intervention available in the FINGER study should be implemented;
that is, dietary counseling, physical exercise, cognitive training, andvas-
cular andmetabolic riskmonitoring.At the same time, local and cultural
adaptations of the content and deliverymethod of the intervention are
encouraged. For instance, dietary counseling will follow national rec-
ommendations while considering country- or region-specific habits. In
MIND-China, for example, dietary guidance puts special emphasis on
reducing salt intake, which is a key dietary challenge in China. In India,
yogamight bepromoted to increase physical exercise, as it is commonly
practiced in some regions. In addition, pharmacological vascular risk
factor management, when applicable, will be based on national care
guidelines. This is essential to improve engagement and adherence, and
subsequently, to facilitate the effective and sustainable implementa-
tion of preventive strategies.
The Harmonization Protocol indicates that similar tools to detect
cognitive changes are recommended in all new WW-FINGERS trials.
When this is not possible, test batteries similar to the original but
validated in the local settings can be used. There is also the possi-
bility for new cognitive outcome scores to be added (eg, in the U.S.
POINTER, some cognitive computer-basedmeasures have been added
as exploratory outcomes). Change in a global measure of cognitive
function is the primary efficacy outcome in WW-FINGERS trials, but
direct translation of cognitive assessments tools into different lan-
guages and in a manner that is relevant to different cultures and pop-
ulations may not always be possible or feasible. In addition, educa-
tion can influence factors for cognitive assessment and performance. It
may be possible, however, to harmonize cognitive outcomes across dis-
parate populations with respect to the cognitive domains tested. In the
FINGER study, themajor domains assessed included processing speed,
executive function, and episodic memory. Given cultural differences in
theWW-FINGERSNetwork, assessment of these domainsmay involve
administration of different cognitive tests. Another approach might
be to administer a test that assesses everyday functional memory (as
opposed to rote memory) in ways that are more culturally relevant to
individuals under study.
It should be emphasized that theWW-FINGERS is not a single study
with multiple centers around the world, with unified strict criteria on
harmonized outcomes and interventions. Instead, the aim is to test
the adaptation of the FINGER study in different populations regarding
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feasibility and effectiveness. Thus, the studies in theWW-FINGERSare
separate studies with their own research questions with pooled data
analyses enabled through prospective harmonization, which increases
power and permits subgroup analyses. Indeed, one of the key goals
in the WW-FINGERS is to incorporate diversity, and inclusion of his-
torically underrepresented groups (eg, sex, race, ethnicity, education,
socioeconomic status) is highly encouraged. Pooleddata fromtheWW-
FINGERS Network can provide insight into the potential of multido-
main lifestyle interventions to impact cognitive health and decline
across widely diverse populations.
While full alignment of outcomemeasures across allWW-FINGERS
trials could be challenging regarding cognition and lifestyle, it might
be easier for brain imaging, blood and CSF biomarkers, and clinical
measures, forwhich substantial work toward standardization has been
done. Omics and genome-wide association study data are relatively
new in clinical trials and thus there has been less progress on harmo-
nization. The WW-FINGERS Network will work toward establishing
global standards for sample collection and explore the potential of a
WW-FINGERS biorepository.
Regarding the need for a data sharing platform, the WW-FINGERS
Network will build upon prior work, as well as search for innovative
ICT-solutions (ie, Information and communications technology), gen-
erated by the rapid expansion of data sharing technologies and tools.
For instance, U.S. POINTER will use the Global Alzheimer’s Associa-
tion Interactive Network (GAAIN, gaain.org) as a platform for global
data sharing, as GAAIN can link diverse data sets. ICT solutions can
help overcome the challenges of having data cross country borders,
harmonizing data sets, and allowing for aggregate interrogation in a
secure framework. As the WW-FINGERS Network expands and trials
are launched, data-sharing tools will be assessed as it will be important
for the various initiatives to align so that trial data are analyzed,
interpreted, and validated in a consistent manner and that privacy and
confidentiality are maintained. From the European perspective, given
the current changes in regulation regarding data protection (ie, Euro-
pean General Data Protection Regulation, GDPR),41 sharing individual
level data with countries outside of the European Union is difficult,
even with proper pseudonymization.42 Therefore, instead of sharing
individual level data across the borders, the aim within the WW-
FINGERSNetwork is to create a federated database platform enabling
pooled data analyses remotely.43 Overall, WW-FINGERS aims to
optimize harnessing of data, while accounting for global variations and
increasing requirements for data protection and sharing.
4 NEXT STEPS
WW-FINGERS is the first global networkofmultidomain lifestyle inter-
vention trials for dementia risk reduction and prevention, and aims
to adapt, test, and optimize the FINGER model to prevent dementia
across the entire spectrum of cognitive decline—from at-risk asymp-
tomatic states to early symptomatic stages, such as prodromal AD—
and in different geographical, cultural, and economic settings. Multi-
pleWW-FINGERS studies are in the early stages of initiation in several
countries, targeting subjects with different risk profiles, either with-
out cognitive impairment or with pre-dementia symptomatic cognitive
changes. Multidomain strategies have already been proved effective
and are internationally implemented in guidelines for the prevention
of cardiovascular disease and diabetes mellitus. This supports the scal-
ability that is being developed throughWW-FINGERS.
Overall aims of the WW-FINGERS Network are aligned with the
recent WHO guidelines for risk reduction of cognitive decline and
dementia,26 in which the WHO recommends conducting multido-
main intervention trials similar to FINGER to define evidence-based
approaches to public health preventive interventions. This is espe-
cially crucial for low- andmiddle-income countries (LMICs), which lack
robust evidence on risk and protective factors for dementia and AD,
and yet are expected to face the highest rise in the number of dementia
cases by 2050.1 Toward this end, the Network has started working to
engage and support LMICs as well as other countries (eg, Middle East:
Israel, Iran; Africa: Cameroon, South Africa; Russia, Hungary), and the
close collaboration with the WHO can help disseminating study find-
ings in these areas and potentially expand theWW-FINGERSNetwork.
The WHO recognizes the need for research coordination and har-
monization. In this regard, WW-FINGERS will provide insight on the
challenges that need to be overcome to drive global collaborative
efforts and the implications for research, ethics, and policy. A WW-
FINGERS Harmonization Protocol is being compiled, to ensure that
country-specific WW-FINGERS trials are harmonized with the core
features of the FINGER study, allowing for local adaptations to be
introduced. An Oversight Committee, described in the protocol, plans
to oversee its proper implementation and guide the development of a
set of common data elements, the synchronization of outcomes across
studies engaging diverse populations, and the building of an infrastruc-
ture to support a network-wide data sharing.
In WW-FINGERS, the focus is on individual-based preventive
approaches in personswith increased risk of dementia. AlthoughWW-
FINGERS is not designed to incorporate broader health care and social
policies, thepooledanalyseswill provide theopportunity toexplore the
feasibility and effectiveness of interventions in different health care
and social settings.
Results from WW-FINGERS can be used to potentially update the
WHO recommendations specifically relating to multidomain interven-
tions, and findings from WW-FINGERS trials can be disseminated
though the WHO’s Global Dementia Observatory (GDO), a data and
knowledge exchange platform that offers easy access to key demen-
tia data fromMember States across the following three domains: poli-
cies, service delivery, and information and research. TheGDOsupports
countries in measuring progress on dementia actions outlined in the
GlobalDementiaActionPlanon thePublicHealthResponse toDemen-
tia 2017-2025 and assists them in strengthening policies, service plan-
ning, and health and social care systems for dementia.44
WW-FINGERS will offer numerous opportunities for hypotheses
testing, in addition to those assessing the efficacy ofmultidomain inter-
ventions to slow cognitive decline. For example, several studies are
planning to investigate the relationship of vascular risk factors and vas-
cular disease with dementia. In addition, the rich neuroimaging and
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biorepository collected will enable studies on mediating pathways and
underlying mechanisms of the multidomain interventions, as well as
contribute to identifying risk profiles that may be more responsive to
specific interventions. Together with the introduction of pharmacolog-
ical components within the multidomain lifestyle model, this approach
can facilitate the definition of preventive approacheswithin the frame-
work of precision prevention.
By collectively convening several multidisciplinary research teams,
WW-FINGERS will provide a forum to establish harmonization and
encourage adaptation of the multidomain lifestyle intervention across
various countries and settings, facilitate responsible data sharing and
analysis across studies, establish opportunities for joint initiatives
across country borders, and strengthen the potential evidence base
formultidomain lifestyle interventions toprevent cognitivedecline and
dementia. The WW-FINGERS Network of studies will provide impor-
tant new knowledge that will facilitate the development of effective
interventions and contribute to identifying globally applicable strate-
gies to prevent or delay the onset and progression of late-life cogni-
tive impairment, AD, and dementia. Risk factor modifications by public
health interventions have had a remarkable impact on the occurrence
of cardiovascular disease, and the same can be expected for dementia.
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